Beactica AB: Beactica Therapeutics and Oscotec mutually agre

UPPSALA, Sweden and SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development

Related Keywords

Seoul , Soult Ukpyolsi , South Korea , Sweden , Uppsala , Uppsala Lan , Swedish , Taeyoung Yoon , Oscotec Inc , Drug Administration , Beactica Therapeutics , Orphan Drug Designation , Drug Designation , Beactica , Herapeutics , Scotec , Mutually , Degree , Conclude , Ncology , Collaboration ,